Sandra K.
Sandra K. Jauron, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20080304909 | SEMI-PERMANENT BOLLARD - A bollard mounting system mounts a bollard body to a stationary post mounted in the floor or ground. The bollard mounting system includes a plurality of locking protrusions and a key protrusion coupled with or otherwise integral with the post. The bollard mounting system also includes a keyed collar disposed on the bollard body. When the bollard body and the keyed collar are positioned on the post, the locking protrusions and the key protrusion engage the keyed collar locking the bollard body onto the stationary post. Installation of the bollard body only requires sliding the bollard body with the keyed collar into place over the stationary post. The locking protrusions are not externally accessible and not externally visible after the bollard body is locked in position, which reduces the likelihood of theft or damage to the locking mechanism in an aesthetically desirable manner. | 12-11-2008 |
20100172692 | BOLLARD HAVING AN IMPACT ABSORPTION MECHANISM - A plate-mounted bollard which includes an internal impact absorption mechanism that enables the bollard to absorb impact forces greater than conventional plate-mounted bollards. The bollard makes use of a force transfer process that shifts impact forces to areas better able to resiliently absorb the impact without causing damage to the bollard, the impact absorption mechanism, or the ground in which the bollard is installed. The impact absorption mechanism consists of an internal resilient core rod mounted at its proximal end to a base plate which is fixed to the ground. Impact forces are then transferred through an outer shell to the distal or upper end of the internal resilient core. With energy from the impact force being distributed along the maximum length of the resilient core rod, the rod flexes and the full length of the rod is utilized to absorb the impact energy. | 07-08-2010 |
Sandra K. Klimuk, Vancouver CA
Patent application number | Description | Published |
---|---|---|
20080200417 | HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES - Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%. | 08-21-2008 |
20120114831 | HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES - Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%. | 05-10-2012 |
Sandra K. Ruscetti, New Market, MD US
Patent application number | Description | Published |
---|---|---|
20100167268 | SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related disease such as an XMRV-related neuroimmune disease such as chronic fatigue syndrome or an XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity of antibodies against XMRV in a sample from a subject. | 07-01-2010 |
20110117056 | DIAGNOSIS AND TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH XENOTROPIC MURINE LEUKEMIA VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV immunopeptide, an XMRV antigen, or an XMRV nucleic acid in a sample from a subject. Therapeutic methods of treatment with anti-retroviral agents are also disclosed. Further disclosed are assays for testing compounds having activity against XMRV. | 05-19-2011 |
Sandra K. Stolz-Dunn, Midland, MI US
Patent application number | Description | Published |
---|---|---|
20110172368 | Radically Functionalized Olefin-Based Polymer with Reduced Molecular Weight Change and Method - The present disclosure provides a functionalized olefin-based polymer, a process for producing the same, and articles containing the functionalized olefin-based polymer. The functionalized olefin-based polymer includes an olefin-based polymer, and a functional agent grafted to the olefin-based polymer by way of a coagent. The coagent is either a cinnamoyl derivative and/or a cyano-acrylate compound. The presence of the coagent inhibits a change in the molecular weight during radical functionalization of the olefin-based polymer. | 07-14-2011 |